Summary of immunologic and clinical data
| Patient subject no. | Dendritic cell dose (×106) | Tumor status at initiation of dendritic cell treatment | ↑ Systemic CTL activity* | TGF-β2 expression† | Intracranial T-cell infiltration‡ (post-vaccination) | TTP (mo) | Overall survival (mo) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | ND | + | 1.68 | ++++ | 18.1 | 30.2 |
| 2 | 1 | PD | − | 5.78 | − | 8.4 | 11.4 |
| 3 | 1 | ND | + | 0.66 | +++ | 27 | 38.9 |
| 4 | 5 | SD | + | 1.08 | +++ | 19.9 | 35.8 |
| 5 | 5 | SD | + | 0.25 | NA | No progression | >58.0 |
| 6 | 5 | SD | + | 1.89 | NA | 14.5 | 25.6 |
| 7 | 10 | PD | − | 5.63 | − | 6.6 | 11.9 |
| 8 | 10 | SD | − | 2.54 | + | 16.5 | 21.2 |
| 9 | 10 | ND | + | 0.32 | ++++ | 28.5 | >48.4 |
| 10 | 10 | PD | − | 3.16 | NA | 9.1 | 18.0 |
| 11 | 10 | PD | − | 2.33 | NA | 5.7 | 12.0 |
| 12 | 10 | PD | − | 6.88 | − | 3.2 | 7.3 |
Abbreviations: SD, stable disease; PD, progressive disease; ND, no measurable disease; NA, not available because no surgery was done post-vaccination.
↵* “Positive” CTL response was set as % specific lysis post-vaccine (d 35) >2× magnitude of % specific lysis pre-vaccine (d −14) at two or more E/T ratios.
↵† TGF-β2 expression is presented as quantitative units relative to primer controls and normalized to glyceraldehyde-3-phosphate dehydrogenase expression.
↵‡ Scored by semiquantitative assessment of number of CD8+ TILs.